nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—ABCG2—Sulfasalazine—ankylosing spondylitis	0.2	0.215	CbGbCtD
Vemurafenib—ABCC1—Methotrexate—ankylosing spondylitis	0.12	0.129	CbGbCtD
Vemurafenib—ALB—Prednisone—ankylosing spondylitis	0.11	0.119	CbGbCtD
Vemurafenib—ABCG2—Dexamethasone—ankylosing spondylitis	0.0999	0.107	CbGbCtD
Vemurafenib—ABCG2—Methotrexate—ankylosing spondylitis	0.0803	0.0863	CbGbCtD
Vemurafenib—CYP3A4—Methylprednisolone—ankylosing spondylitis	0.057	0.0614	CbGbCtD
Vemurafenib—ALB—Methotrexate—ankylosing spondylitis	0.0553	0.0595	CbGbCtD
Vemurafenib—CYP3A4—Triamcinolone—ankylosing spondylitis	0.0432	0.0465	CbGbCtD
Vemurafenib—CYP3A4—Betamethasone—ankylosing spondylitis	0.0371	0.0399	CbGbCtD
Vemurafenib—CYP3A4—Prednisolone—ankylosing spondylitis	0.0366	0.0394	CbGbCtD
Vemurafenib—CYP3A4—Prednisone—ankylosing spondylitis	0.0346	0.0372	CbGbCtD
Vemurafenib—CYP2D6—Dexamethasone—ankylosing spondylitis	0.0339	0.0365	CbGbCtD
Vemurafenib—CYP3A4—Dexamethasone—ankylosing spondylitis	0.0216	0.0232	CbGbCtD
Vemurafenib—Sunburn—Methotrexate—ankylosing spondylitis	0.002	0.0285	CcSEcCtD
Vemurafenib—Folliculitis—Triamcinolone—ankylosing spondylitis	0.00146	0.0207	CcSEcCtD
Vemurafenib—Folliculitis—Methylprednisolone—ankylosing spondylitis	0.00145	0.0207	CcSEcCtD
Vemurafenib—Folliculitis—Dexamethasone—ankylosing spondylitis	0.00132	0.0188	CcSEcCtD
Vemurafenib—Folliculitis—Betamethasone—ankylosing spondylitis	0.00132	0.0188	CcSEcCtD
Vemurafenib—Vasculitis—Prednisolone—ankylosing spondylitis	0.00102	0.0145	CcSEcCtD
Vemurafenib—Polyp—Methotrexate—ankylosing spondylitis	0.000994	0.0141	CcSEcCtD
Vemurafenib—Folliculitis—Methotrexate—ankylosing spondylitis	0.000962	0.0137	CcSEcCtD
Vemurafenib—Vasculitis—Triamcinolone—ankylosing spondylitis	0.000938	0.0133	CcSEcCtD
Vemurafenib—Vasculitis—Methylprednisolone—ankylosing spondylitis	0.000936	0.0133	CcSEcCtD
Vemurafenib—Cyst—Methotrexate—ankylosing spondylitis	0.000905	0.0129	CcSEcCtD
Vemurafenib—Paralysis—Methotrexate—ankylosing spondylitis	0.00087	0.0124	CcSEcCtD
Vemurafenib—Vasculitis—Betamethasone—ankylosing spondylitis	0.000851	0.0121	CcSEcCtD
Vemurafenib—Vasculitis—Dexamethasone—ankylosing spondylitis	0.000851	0.0121	CcSEcCtD
Vemurafenib—Hepatotoxicity—Methotrexate—ankylosing spondylitis	0.000783	0.0111	CcSEcCtD
Vemurafenib—Vasculitis—Prednisone—ankylosing spondylitis	0.000741	0.0105	CcSEcCtD
Vemurafenib—Dry skin—Prednisolone—ankylosing spondylitis	0.000662	0.00942	CcSEcCtD
Vemurafenib—Vasculitis—Methotrexate—ankylosing spondylitis	0.00062	0.00881	CcSEcCtD
Vemurafenib—Dry skin—Betamethasone—ankylosing spondylitis	0.000553	0.00786	CcSEcCtD
Vemurafenib—Dry skin—Dexamethasone—ankylosing spondylitis	0.000553	0.00786	CcSEcCtD
Vemurafenib—Neoplasm—Methotrexate—ankylosing spondylitis	0.000547	0.00777	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Prednisolone—ankylosing spondylitis	0.000546	0.00776	CcSEcCtD
Vemurafenib—Infestation NOS—Methylprednisolone—ankylosing spondylitis	0.000511	0.00727	CcSEcCtD
Vemurafenib—Infestation—Methylprednisolone—ankylosing spondylitis	0.000511	0.00727	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Triamcinolone—ankylosing spondylitis	0.000502	0.00714	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Methylprednisolone—ankylosing spondylitis	0.000501	0.00712	CcSEcCtD
Vemurafenib—Photosensitivity—Methotrexate—ankylosing spondylitis	0.0005	0.00711	CcSEcCtD
Vemurafenib—Dry skin—Prednisone—ankylosing spondylitis	0.000481	0.00685	CcSEcCtD
Vemurafenib—Weight decreased—Betamethasone—ankylosing spondylitis	0.000472	0.00671	CcSEcCtD
Vemurafenib—Weight decreased—Dexamethasone—ankylosing spondylitis	0.000472	0.00671	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Dexamethasone—ankylosing spondylitis	0.000456	0.00648	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Betamethasone—ankylosing spondylitis	0.000456	0.00648	CcSEcCtD
Vemurafenib—Connective tissue disorder—Methylprednisolone—ankylosing spondylitis	0.000451	0.00641	CcSEcCtD
Vemurafenib—Erythema—Prednisolone—ankylosing spondylitis	0.000435	0.00619	CcSEcCtD
Vemurafenib—Eye disorder—Methylprednisolone—ankylosing spondylitis	0.000429	0.0061	CcSEcCtD
Vemurafenib—Cardiac disorder—Methylprednisolone—ankylosing spondylitis	0.000426	0.00605	CcSEcCtD
Vemurafenib—Angiopathy—Methylprednisolone—ankylosing spondylitis	0.000416	0.00592	CcSEcCtD
Vemurafenib—Mediastinal disorder—Methylprednisolone—ankylosing spondylitis	0.000413	0.00588	CcSEcCtD
Vemurafenib—Weight decreased—Prednisone—ankylosing spondylitis	0.000411	0.00584	CcSEcCtD
Vemurafenib—Erythema—Triamcinolone—ankylosing spondylitis	0.0004	0.00569	CcSEcCtD
Vemurafenib—Erythema—Methylprednisolone—ankylosing spondylitis	0.000399	0.00568	CcSEcCtD
Vemurafenib—Malnutrition—Methylprednisolone—ankylosing spondylitis	0.000399	0.00568	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Prednisone—ankylosing spondylitis	0.000397	0.00564	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Methotrexate—ankylosing spondylitis	0.000395	0.00562	CcSEcCtD
Vemurafenib—Dysgeusia—Triamcinolone—ankylosing spondylitis	0.000392	0.00557	CcSEcCtD
Vemurafenib—Eye disorder—Betamethasone—ankylosing spondylitis	0.00039	0.00554	CcSEcCtD
Vemurafenib—Eye disorder—Dexamethasone—ankylosing spondylitis	0.00039	0.00554	CcSEcCtD
Vemurafenib—Back pain—Triamcinolone—ankylosing spondylitis	0.000387	0.00551	CcSEcCtD
Vemurafenib—Angiopathy—Betamethasone—ankylosing spondylitis	0.000379	0.00538	CcSEcCtD
Vemurafenib—Angiopathy—Dexamethasone—ankylosing spondylitis	0.000379	0.00538	CcSEcCtD
Vemurafenib—Eosinophilia—Methotrexate—ankylosing spondylitis	0.000376	0.00534	CcSEcCtD
Vemurafenib—Alopecia—Betamethasone—ankylosing spondylitis	0.000369	0.00524	CcSEcCtD
Vemurafenib—Alopecia—Dexamethasone—ankylosing spondylitis	0.000369	0.00524	CcSEcCtD
Vemurafenib—Erythema—Betamethasone—ankylosing spondylitis	0.000363	0.00516	CcSEcCtD
Vemurafenib—Erythema—Dexamethasone—ankylosing spondylitis	0.000363	0.00516	CcSEcCtD
Vemurafenib—Connective tissue disorder—Prednisone—ankylosing spondylitis	0.000357	0.00508	CcSEcCtD
Vemurafenib—Anaphylactic shock—Prednisolone—ankylosing spondylitis	0.000355	0.00505	CcSEcCtD
Vemurafenib—Cough—Triamcinolone—ankylosing spondylitis	0.000349	0.00497	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Methotrexate—ankylosing spondylitis	0.000346	0.00492	CcSEcCtD
Vemurafenib—Myalgia—Triamcinolone—ankylosing spondylitis	0.000341	0.00485	CcSEcCtD
Vemurafenib—Arthralgia—Methylprednisolone—ankylosing spondylitis	0.00034	0.00484	CcSEcCtD
Vemurafenib—Myalgia—Methylprednisolone—ankylosing spondylitis	0.00034	0.00484	CcSEcCtD
Vemurafenib—Eye disorder—Prednisone—ankylosing spondylitis	0.00034	0.00483	CcSEcCtD
Vemurafenib—Infestation NOS—Methotrexate—ankylosing spondylitis	0.000338	0.00481	CcSEcCtD
Vemurafenib—Infestation—Methotrexate—ankylosing spondylitis	0.000338	0.00481	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—ankylosing spondylitis	0.000338	0.0048	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Methotrexate—ankylosing spondylitis	0.000335	0.00477	CcSEcCtD
Vemurafenib—Angiopathy—Prednisone—ankylosing spondylitis	0.00033	0.00469	CcSEcCtD
Vemurafenib—Anaphylactic shock—Triamcinolone—ankylosing spondylitis	0.000327	0.00465	CcSEcCtD
Vemurafenib—Anaphylactic shock—Methylprednisolone—ankylosing spondylitis	0.000326	0.00464	CcSEcCtD
Vemurafenib—Infection—Triamcinolone—ankylosing spondylitis	0.000325	0.00462	CcSEcCtD
Vemurafenib—Infection—Methylprednisolone—ankylosing spondylitis	0.000324	0.0046	CcSEcCtD
Vemurafenib—Alopecia—Prednisone—ankylosing spondylitis	0.000321	0.00457	CcSEcCtD
Vemurafenib—Nervous system disorder—Methylprednisolone—ankylosing spondylitis	0.00032	0.00455	CcSEcCtD
Vemurafenib—Skin disorder—Methylprednisolone—ankylosing spondylitis	0.000317	0.0045	CcSEcCtD
Vemurafenib—Malnutrition—Prednisone—ankylosing spondylitis	0.000316	0.0045	CcSEcCtD
Vemurafenib—Erythema—Prednisone—ankylosing spondylitis	0.000316	0.0045	CcSEcCtD
Vemurafenib—Myalgia—Dexamethasone—ankylosing spondylitis	0.000309	0.0044	CcSEcCtD
Vemurafenib—Myalgia—Betamethasone—ankylosing spondylitis	0.000309	0.0044	CcSEcCtD
Vemurafenib—Hypotension—Methylprednisolone—ankylosing spondylitis	0.000305	0.00433	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Triamcinolone—ankylosing spondylitis	0.000298	0.00423	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Methylprednisolone—ankylosing spondylitis	0.000297	0.00422	CcSEcCtD
Vemurafenib—Anaphylactic shock—Dexamethasone—ankylosing spondylitis	0.000296	0.00422	CcSEcCtD
Vemurafenib—Anaphylactic shock—Betamethasone—ankylosing spondylitis	0.000296	0.00422	CcSEcCtD
Vemurafenib—Infection—Dexamethasone—ankylosing spondylitis	0.000294	0.00419	CcSEcCtD
Vemurafenib—Infection—Betamethasone—ankylosing spondylitis	0.000294	0.00419	CcSEcCtD
Vemurafenib—Nervous system disorder—Betamethasone—ankylosing spondylitis	0.000291	0.00413	CcSEcCtD
Vemurafenib—Nervous system disorder—Dexamethasone—ankylosing spondylitis	0.000291	0.00413	CcSEcCtD
Vemurafenib—Erythema multiforme—Methotrexate—ankylosing spondylitis	0.000287	0.00408	CcSEcCtD
Vemurafenib—Eye disorder—Methotrexate—ankylosing spondylitis	0.000284	0.00404	CcSEcCtD
Vemurafenib—Cardiac disorder—Methotrexate—ankylosing spondylitis	0.000282	0.00401	CcSEcCtD
Vemurafenib—Fatigue—Triamcinolone—ankylosing spondylitis	0.000282	0.00401	CcSEcCtD
Vemurafenib—Fatigue—Methylprednisolone—ankylosing spondylitis	0.000281	0.004	CcSEcCtD
Vemurafenib—Hypotension—Betamethasone—ankylosing spondylitis	0.000277	0.00394	CcSEcCtD
Vemurafenib—Hypotension—Dexamethasone—ankylosing spondylitis	0.000277	0.00394	CcSEcCtD
Vemurafenib—Angiopathy—Methotrexate—ankylosing spondylitis	0.000275	0.00392	CcSEcCtD
Vemurafenib—Mediastinal disorder—Methotrexate—ankylosing spondylitis	0.000274	0.00389	CcSEcCtD
Vemurafenib—Chills—Methotrexate—ankylosing spondylitis	0.000272	0.00387	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Dexamethasone—ankylosing spondylitis	0.00027	0.00384	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Betamethasone—ankylosing spondylitis	0.00027	0.00384	CcSEcCtD
Vemurafenib—Arthralgia—Prednisone—ankylosing spondylitis	0.000269	0.00383	CcSEcCtD
Vemurafenib—Myalgia—Prednisone—ankylosing spondylitis	0.000269	0.00383	CcSEcCtD
Vemurafenib—Alopecia—Methotrexate—ankylosing spondylitis	0.000268	0.00382	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—ankylosing spondylitis	0.000267	0.0038	CcSEcCtD
Vemurafenib—Erythema—Methotrexate—ankylosing spondylitis	0.000264	0.00376	CcSEcCtD
Vemurafenib—Malnutrition—Methotrexate—ankylosing spondylitis	0.000264	0.00376	CcSEcCtD
Vemurafenib—Hypersensitivity—Prednisolone—ankylosing spondylitis	0.000262	0.00372	CcSEcCtD
Vemurafenib—Dysgeusia—Methotrexate—ankylosing spondylitis	0.000259	0.00368	CcSEcCtD
Vemurafenib—Body temperature increased—Triamcinolone—ankylosing spondylitis	0.000258	0.00367	CcSEcCtD
Vemurafenib—Anaphylactic shock—Prednisone—ankylosing spondylitis	0.000258	0.00367	CcSEcCtD
Vemurafenib—Decreased appetite—Dexamethasone—ankylosing spondylitis	0.000258	0.00366	CcSEcCtD
Vemurafenib—Decreased appetite—Betamethasone—ankylosing spondylitis	0.000258	0.00366	CcSEcCtD
Vemurafenib—Infection—Prednisone—ankylosing spondylitis	0.000256	0.00365	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Dexamethasone—ankylosing spondylitis	0.000256	0.00364	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Betamethasone—ankylosing spondylitis	0.000256	0.00364	CcSEcCtD
Vemurafenib—Back pain—Methotrexate—ankylosing spondylitis	0.000256	0.00364	CcSEcCtD
Vemurafenib—Fatigue—Dexamethasone—ankylosing spondylitis	0.000256	0.00363	CcSEcCtD
Vemurafenib—Fatigue—Betamethasone—ankylosing spondylitis	0.000256	0.00363	CcSEcCtD
Vemurafenib—Nervous system disorder—Prednisone—ankylosing spondylitis	0.000253	0.0036	CcSEcCtD
Vemurafenib—Skin disorder—Prednisone—ankylosing spondylitis	0.000251	0.00357	CcSEcCtD
Vemurafenib—Hypersensitivity—Triamcinolone—ankylosing spondylitis	0.000241	0.00342	CcSEcCtD
Vemurafenib—Hypersensitivity—Methylprednisolone—ankylosing spondylitis	0.00024	0.00342	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Prednisone—ankylosing spondylitis	0.000235	0.00334	CcSEcCtD
Vemurafenib—Dizziness—Prednisolone—ankylosing spondylitis	0.000235	0.00334	CcSEcCtD
Vemurafenib—Asthenia—Triamcinolone—ankylosing spondylitis	0.000234	0.00333	CcSEcCtD
Vemurafenib—Body temperature increased—Betamethasone—ankylosing spondylitis	0.000234	0.00333	CcSEcCtD
Vemurafenib—Body temperature increased—Dexamethasone—ankylosing spondylitis	0.000234	0.00333	CcSEcCtD
Vemurafenib—Asthenia—Methylprednisolone—ankylosing spondylitis	0.000234	0.00333	CcSEcCtD
Vemurafenib—Pruritus—Triamcinolone—ankylosing spondylitis	0.000231	0.00329	CcSEcCtD
Vemurafenib—Cough—Methotrexate—ankylosing spondylitis	0.000231	0.00328	CcSEcCtD
Vemurafenib—Pruritus—Methylprednisolone—ankylosing spondylitis	0.000231	0.00328	CcSEcCtD
Vemurafenib—Myalgia—Methotrexate—ankylosing spondylitis	0.000225	0.0032	CcSEcCtD
Vemurafenib—Arthralgia—Methotrexate—ankylosing spondylitis	0.000225	0.0032	CcSEcCtD
Vemurafenib—Decreased appetite—Prednisone—ankylosing spondylitis	0.000224	0.00319	CcSEcCtD
Vemurafenib—Rash—Prednisolone—ankylosing spondylitis	0.000224	0.00319	CcSEcCtD
Vemurafenib—Dermatitis—Prednisolone—ankylosing spondylitis	0.000224	0.00318	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—ankylosing spondylitis	0.000223	0.00318	CcSEcCtD
Vemurafenib—Diarrhoea—Methylprednisolone—ankylosing spondylitis	0.000223	0.00317	CcSEcCtD
Vemurafenib—Fatigue—Prednisone—ankylosing spondylitis	0.000223	0.00316	CcSEcCtD
Vemurafenib—Headache—Prednisolone—ankylosing spondylitis	0.000223	0.00316	CcSEcCtD
Vemurafenib—Constipation—Prednisone—ankylosing spondylitis	0.000221	0.00314	CcSEcCtD
Vemurafenib—Dizziness—Triamcinolone—ankylosing spondylitis	0.000216	0.00307	CcSEcCtD
Vemurafenib—Anaphylactic shock—Methotrexate—ankylosing spondylitis	0.000216	0.00307	CcSEcCtD
Vemurafenib—Dizziness—Methylprednisolone—ankylosing spondylitis	0.000216	0.00307	CcSEcCtD
Vemurafenib—Infection—Methotrexate—ankylosing spondylitis	0.000214	0.00305	CcSEcCtD
Vemurafenib—Asthenia—Betamethasone—ankylosing spondylitis	0.000213	0.00302	CcSEcCtD
Vemurafenib—Asthenia—Dexamethasone—ankylosing spondylitis	0.000213	0.00302	CcSEcCtD
Vemurafenib—Nervous system disorder—Methotrexate—ankylosing spondylitis	0.000212	0.00301	CcSEcCtD
Vemurafenib—Nausea—Prednisolone—ankylosing spondylitis	0.000211	0.003	CcSEcCtD
Vemurafenib—Pruritus—Dexamethasone—ankylosing spondylitis	0.00021	0.00298	CcSEcCtD
Vemurafenib—Pruritus—Betamethasone—ankylosing spondylitis	0.00021	0.00298	CcSEcCtD
Vemurafenib—Skin disorder—Methotrexate—ankylosing spondylitis	0.00021	0.00298	CcSEcCtD
Vemurafenib—Vomiting—Triamcinolone—ankylosing spondylitis	0.000208	0.00295	CcSEcCtD
Vemurafenib—Vomiting—Methylprednisolone—ankylosing spondylitis	0.000207	0.00295	CcSEcCtD
Vemurafenib—Rash—Triamcinolone—ankylosing spondylitis	0.000206	0.00293	CcSEcCtD
Vemurafenib—Dermatitis—Triamcinolone—ankylosing spondylitis	0.000206	0.00293	CcSEcCtD
Vemurafenib—Rash—Methylprednisolone—ankylosing spondylitis	0.000206	0.00292	CcSEcCtD
Vemurafenib—Dermatitis—Methylprednisolone—ankylosing spondylitis	0.000205	0.00292	CcSEcCtD
Vemurafenib—Headache—Triamcinolone—ankylosing spondylitis	0.000205	0.00291	CcSEcCtD
Vemurafenib—Headache—Methylprednisolone—ankylosing spondylitis	0.000204	0.0029	CcSEcCtD
Vemurafenib—Body temperature increased—Prednisone—ankylosing spondylitis	0.000204	0.0029	CcSEcCtD
Vemurafenib—Diarrhoea—Dexamethasone—ankylosing spondylitis	0.000203	0.00288	CcSEcCtD
Vemurafenib—Diarrhoea—Betamethasone—ankylosing spondylitis	0.000203	0.00288	CcSEcCtD
Vemurafenib—Hypotension—Methotrexate—ankylosing spondylitis	0.000202	0.00287	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Methotrexate—ankylosing spondylitis	0.000197	0.0028	CcSEcCtD
Vemurafenib—Dizziness—Dexamethasone—ankylosing spondylitis	0.000196	0.00279	CcSEcCtD
Vemurafenib—Dizziness—Betamethasone—ankylosing spondylitis	0.000196	0.00279	CcSEcCtD
Vemurafenib—Nausea—Triamcinolone—ankylosing spondylitis	0.000194	0.00276	CcSEcCtD
Vemurafenib—Nausea—Methylprednisolone—ankylosing spondylitis	0.000194	0.00275	CcSEcCtD
Vemurafenib—Hypersensitivity—Prednisone—ankylosing spondylitis	0.00019	0.0027	CcSEcCtD
Vemurafenib—Vomiting—Betamethasone—ankylosing spondylitis	0.000188	0.00268	CcSEcCtD
Vemurafenib—Vomiting—Dexamethasone—ankylosing spondylitis	0.000188	0.00268	CcSEcCtD
Vemurafenib—Decreased appetite—Methotrexate—ankylosing spondylitis	0.000188	0.00267	CcSEcCtD
Vemurafenib—Rash—Betamethasone—ankylosing spondylitis	0.000187	0.00266	CcSEcCtD
Vemurafenib—Rash—Dexamethasone—ankylosing spondylitis	0.000187	0.00266	CcSEcCtD
Vemurafenib—Dermatitis—Betamethasone—ankylosing spondylitis	0.000187	0.00266	CcSEcCtD
Vemurafenib—Dermatitis—Dexamethasone—ankylosing spondylitis	0.000187	0.00266	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Methotrexate—ankylosing spondylitis	0.000186	0.00265	CcSEcCtD
Vemurafenib—Fatigue—Methotrexate—ankylosing spondylitis	0.000186	0.00264	CcSEcCtD
Vemurafenib—Headache—Betamethasone—ankylosing spondylitis	0.000186	0.00264	CcSEcCtD
Vemurafenib—Headache—Dexamethasone—ankylosing spondylitis	0.000186	0.00264	CcSEcCtD
Vemurafenib—Asthenia—Prednisone—ankylosing spondylitis	0.000185	0.00263	CcSEcCtD
Vemurafenib—Pruritus—Prednisone—ankylosing spondylitis	0.000183	0.0026	CcSEcCtD
Vemurafenib—Diarrhoea—Prednisone—ankylosing spondylitis	0.000177	0.00251	CcSEcCtD
Vemurafenib—Nausea—Betamethasone—ankylosing spondylitis	0.000176	0.0025	CcSEcCtD
Vemurafenib—Nausea—Dexamethasone—ankylosing spondylitis	0.000176	0.0025	CcSEcCtD
Vemurafenib—Dizziness—Prednisone—ankylosing spondylitis	0.000171	0.00243	CcSEcCtD
Vemurafenib—Body temperature increased—Methotrexate—ankylosing spondylitis	0.000171	0.00243	CcSEcCtD
Vemurafenib—Vomiting—Prednisone—ankylosing spondylitis	0.000164	0.00233	CcSEcCtD
Vemurafenib—Rash—Prednisone—ankylosing spondylitis	0.000163	0.00231	CcSEcCtD
Vemurafenib—Dermatitis—Prednisone—ankylosing spondylitis	0.000163	0.00231	CcSEcCtD
Vemurafenib—Headache—Prednisone—ankylosing spondylitis	0.000162	0.0023	CcSEcCtD
Vemurafenib—Hypersensitivity—Methotrexate—ankylosing spondylitis	0.000159	0.00226	CcSEcCtD
Vemurafenib—Asthenia—Methotrexate—ankylosing spondylitis	0.000155	0.0022	CcSEcCtD
Vemurafenib—Nausea—Prednisone—ankylosing spondylitis	0.000153	0.00218	CcSEcCtD
Vemurafenib—Pruritus—Methotrexate—ankylosing spondylitis	0.000153	0.00217	CcSEcCtD
Vemurafenib—Diarrhoea—Methotrexate—ankylosing spondylitis	0.000148	0.0021	CcSEcCtD
Vemurafenib—Dizziness—Methotrexate—ankylosing spondylitis	0.000143	0.00203	CcSEcCtD
Vemurafenib—Vomiting—Methotrexate—ankylosing spondylitis	0.000137	0.00195	CcSEcCtD
Vemurafenib—Rash—Methotrexate—ankylosing spondylitis	0.000136	0.00193	CcSEcCtD
Vemurafenib—Dermatitis—Methotrexate—ankylosing spondylitis	0.000136	0.00193	CcSEcCtD
Vemurafenib—Headache—Methotrexate—ankylosing spondylitis	0.000135	0.00192	CcSEcCtD
Vemurafenib—Nausea—Methotrexate—ankylosing spondylitis	0.000128	0.00182	CcSEcCtD
